The Growing Field of Radioligand Therapy and Radium Use for mHSPC and mCRPC

6 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
David Morris, MD, FACS; John Phillips, MD; Jeremy McDuffie, MD; Katy Beckermann, MD, PhD; and Alan Tan, MD, discuss the evolving role of radioligand therapy (RLT) and radium-223 in managing metastatic hormone-sensitive and castration-resistant prostate cancer in part four of their roundtable discussion. The group explores the shift in radium use from a last-resort option to an earlier intervention, the challenges posed by emerging therapies like lutetium, and the increasing accessibility of RLT in clinical practice. Dr. Phillips highlights the promise of radioligand advancements, the growing enthusiasm within radiation oncology, and the potential impact of trials like PEACE-3 in redefining treatment timing and patient outcomes.

#prostatecancer #prostatecarcinoma #oncology #cancer #cancerresearch #healthcare
Category
Oncology
Be the first to comment

Up Next